FDA approves Invega Hayfera (6-month paliperidone palmitate), first and only twice-yearly treatment for adults with schizophrenia – Janssen Pharmaceuticals
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the… read more.
